Wednesday, December 7, 2011
Isis Pharmaceuticals Inc., of Carlsbad, Calif., reported Phase I results showing that its ISIS-APOCIIIRx treatment produced rapid, dose-dependent reductions of up to 78 percent in apolipoprotein C-III protein and up to 44 percent in blood triglyceride levels in healthy volunteers. The drug, which targets the apoC-III gene, also was found to be safe and well tolerated. Data were presented at the Cold Spring Harbor Laboratory RNA Therapeutics meeting in New York.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.